Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01795144 · ClinicalTrials.gov registry record · Phase 1
Incretin Regulation of Insulin Secretion in Monogenic Diabetes
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01795144 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 10 participants.
The verdict
NCT01795144, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.
Interventions
- DRUG GLP-1
- DRUG Exendin 9-39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01795144
The ClinicalTrials.gov registry entry for NCT01795144 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GLP-1 is the first listed.
NCT01795144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01795144 about?
NCT01795144 is a clinical study titled "Incretin Regulation of Insulin Secretion in Monogenic Diabetes". The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.
What is the current status of trial NCT01795144?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01795144?
The interventions under investigation include: GLP-1 (DRUG), Exendin 9-39 (DRUG).
Who is sponsoring clinical trial NCT01795144?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.